{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:25:04Z","timestamp":1793330704463,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019748","name":"Johns Hopkins University Press","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jcpo.2024.100529","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T11:59:54Z","timestamp":1733486394000},"page":"100529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Financial conflicts among physician speakers at the April 12, 2024 Oncology Drug Advisory Meeting: Who decided that MRD can be a novel regulatory endpoint in myeloma?"],"prefix":"10.1016","volume":"43","author":[{"given":"Noah J.","family":"Carr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2024.100529_bib1","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/ajg.2014.85","article-title":"FDA-related matters committee of the American College of Gastroenterology, the food and drug administration advisory committees and panels: how they are applied to the drug regulatory process","volume":"109","author":"Ciociola","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jcpo.2024.100529_bib2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.mayocp.2019.12.002","article-title":"Oncology drug advisory committee recommendations and the US Food and Drug Administration\u2019s Actions","volume":"95","author":"Haslam","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jcpo.2024.100529_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.1718","article-title":"Association of advisory committee votes with US Food and Drug administration decision-making on prescription drugs, 2010-2021","volume":"4","author":"Daval","year":"2023","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.jcpo.2024.100529_bib4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","article-title":"Minimal residual disease in multiple myeloma: bringing the bench to the bedside","volume":"12","author":"Mailankody","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jcpo.2024.100529_bib5","unstructured":"U.S. Food and Drug Administration, April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee- Transcript, (2024). \u3008https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/april-12-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04122024\u3009."},{"key":"10.1016\/j.jcpo.2024.100529_bib6","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jcpo.2024.100529_bib7","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.jcpo.2024.100529_bib8","doi-asserted-by":"crossref","first-page":"e1055","DOI":"10.1016\/S2214-109X(21)00202-3","article-title":"Conflicts of interest: an invisible force shaping health systems and policies","volume":"9","author":"Rahman-Shepherd","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.jcpo.2024.100529_bib9","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1002\/cncr.32997","article-title":"Financial conflicts of interest among National Comprehensive Cancer Network clinical practice guideline panelists in 2019","volume":"126","author":"Desai","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jcpo.2024.100529_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14184","article-title":"Financial conflicts of interest among presenters, panellists and moderators at haematology and oncology FDA workshops","volume":"54","author":"Miller","year":"2024","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.jcpo.2024.100529_bib11","doi-asserted-by":"crossref","first-page":"e1164","DOI":"10.1200\/OP.21.00756","article-title":"Industry relationships with medical oncologists: who are the high-payment physicians?","volume":"18","author":"Wright","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.jcpo.2024.100529_bib12","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2006.09.3633","article-title":"Frequency, type, and monetary value of financial conflicts of interest in cancer clinical research","volume":"25","author":"Hampson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcpo.2024.100529_bib13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1200\/JCO.2014.57.8898","article-title":"Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs","volume":"33","author":"Tibau","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcpo.2024.100529_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175493","article-title":"Association between physicians\u2019 interaction with pharmaceutical companies and their clinical practices: a systematic review and meta-analysis","volume":"12","author":"Brax","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jcpo.2024.100529_bib15","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jama.2022.23968","article-title":"Association between drug characteristics and manufacturer spending on direct-to-consumer advertising","volume":"329","author":"DiStefano","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jcpo.2024.100529_bib16","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamainternmed.2022.4924","article-title":"Association between US drug price and measures of efficacy for oncology drugs approved by the US Food and Drug Administration From 2015 to 2020","volume":"182","author":"Miljkovi\u0107","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jcpo.2024.100529_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0026","article-title":"Assessment of public opinion on transparency at the US Food and Drug Administration","volume":"5","author":"Azad","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jcpo.2024.100529_bib18","unstructured":"ODAC 4.12.24 transcript, n.d."},{"key":"10.1016\/j.jcpo.2024.100529_bib19","article-title":"Characteristics and conflicts of interest at Food and Drug Administration Gastrointestinal Drug Advisory Committee meetings","volume":"16","author":"Khan","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jcpo.2024.100529_bib20","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.295.16.1921","article-title":"Financial conflict of interest disclosure and voting patterns at food and drug administration drug advisory committee meetings","volume":"295","author":"Lurie","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jcpo.2024.100529_bib21","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1001\/jamainternmed.2017.1917","article-title":"Association of appearance of conflicts of interest with voting behavior at FDA advisory committee meetings\u2014a cross-sectional study","volume":"177","author":"Xu","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jcpo.2024.100529_bib22","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1001\/jama.2018.17593","article-title":"Conflicts of interests, authors, and journals: new challenges for a persistent problem","volume":"320","author":"Bauchner","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jcpo.2024.100529_bib23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1056\/NEJMp2114495","article-title":"Transparency and the doctor\u2013patient relationship \u2014 rethinking conflict-of-interest disclosures","volume":"386","author":"Adashi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2024.100529_bib24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1200\/OP.24.00032","article-title":"Financial conflicts of interest: payment at the expense of patients?","volume":"20","author":"Sanford","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.jcpo.2024.100529_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.101","article-title":"Conflict of interest in academic oncology: moving beyond the blame game and forging a path forward","volume":"6","author":"Prasad","year":"2016","journal-title":"Blood Cancer J."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538324000638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538324000638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:40:27Z","timestamp":1777362027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538324000638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":25,"alternative-id":["S2213538324000638"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2024.100529","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Financial conflicts among physician speakers at the April 12, 2024 Oncology Drug Advisory Meeting: Who decided that MRD can be a novel regulatory endpoint in myeloma?","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2024.100529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100529"}}